DNA mismatch repair status affects cellular response to Ara-C and other anti-leukemic nucleoside analogs Nucleoside analogs form the backbone of therapeutic regimes for acute myeloid leukemia (AML) and are used to treat numerous other hematological malignancies, including B-cell acute lymphoblastic leukemia and Hodgkin lymphoma. Chemoresistance presents a major obstacle to the successful treatment of both relapsed and therapy-related AML (t-AML), and altered DNA repair function is one possible mechanism underlying this phenotype.
Microsatellite instability, indicative of defective DNA mismatch repair (MMR) is a rare finding in de novo AML but is common in relapsed AML and t-AML, in which it is reported to occur in 30-90% of cases.
1-3 DNA MMR is responsible for maintaining the integrity of the genome by mediating repair of spontaneous DNA damage arising during DNA replication. The MutSa heterodimer (comprising hMSH2 and hMSH6) initiates repair of base/base mispairs. A second complex, MutSb (comprising hMSH2 and hMSH3), mediates repair of shortand long insertion-deletion loops, but has no activity toward mispairs. Subsequent recruitment of the MutLa heterodimer (hMLH1 and hPMS2) facilitates strand excision and gap filling, restoring the DNA to its original structure. Paradoxically, functional DNA MMR facilitates cytotoxicity of certain chemotherapeutic agents, including methylating agents and the base analog 6-thioguanine (6-TG). In both the cases, the mechanisms leading to cell death remain unclear, although one hypothesis suggests that recognition of O 6 -Me G:T or Me 6-TG:T mispairs in DNA by MutSa leads to repeated abortive repair, ultimately resulting in the formation of pro-cytotoxic DNA strand breaks.
1 MMR-defective cells lack the capacity to recognize mispairs and consequently demonstrate a 'tolerant' phenotype and chemoresistance.
The cytotoxicity of Ara-C is mediated in part by incorporation into replicating DNA leading to inhibition of chain extension, stalling of replication forks, activation of the S-phase checkpoint and cell cycle arrest. However, the presence of Ara-C residues at internucleotide linkage positions in leukemic cells treated in vitro provides evidence that Ara-C is not an absolute chain terminator and that extension can occur following incorporation into DNA. 4 Given this, we hypothesized that incorporation of Ara-C might generate a substrate recognized by the MMR machinery and that, as in the case of 6-TG, cellular response to Ara-C-induced toxicity is influenced by MMR status.
MT-1, a B-lymphoblastoid cell line mutated in both copies of MSH6, expressed almost negligible levels of hMSH6 protein compared with its MMR-proficient parental cell line, TK6 (assessed by western immunoblotting). Loss of MSH6 was accompanied by an approximate 50% decrease in hMSH2 protein but no difference in hMSH3 (Figure 1a ). MT-1 was less sensitive to the cytotoxic effects of the methylating agent N-methyl-N-nitrosourea (MNU) (Figure 1b ) and to 6-TG ( Figure 1c ) compared with parental TK6 cells, consistent with the established tolerance of MT-1 to these agents and its known defect in DNA MMR. MT-1 and TK6 also displayed differential toxicity to Ara-C, consistent with a role for DNA MMR in affecting cellular response to this nucleoside analog. However, in contrast to the phenotype observed following treatment with 6-TG, DNA MMR-defective MT-1 cells were acutely sensitive to Ara-C relative to parental TK6 cells (Figure 1d ).
We next investigated whether MMR status affects cellular response to other nucleoside analogs used in the treatment of hematological malignancy. Clofarabine and fludarabine, like Ara-C, are good substrates for incorporation into DNA by DNA polymerases. Cellular response following treatment with each of these agents was consistent with that observed following treatment with Ara-C, in that MMR-defective MT-1 cells were more sensitive relative to MMR-competent parental TK6 cells (Figures 1e and f) . There was no significant difference in sensitivity to UV radiation between TK6 and MT-1 ( Figure 1g ). Given that UV radiation is not thought to induce lesions, which are substrates for DNA MMR, this finding excludes a generic DNA repair defect in MT-1. These data suggest that the role of DNA MMR as a modulator of cellular response to nucleoside analogs are not limited to the pyrimidine analog Ara-C, but can be extended to other arabinosyl nucleoside analogs. Moreover, the mode of interaction is clearly different to that reported for 6-TG and methylating agents.
To investigate the effect of defects in specific components of DNA MMR, we developed fully isogenic cell line pairs using short-hairpin RNA-mediated gene interference to reduce expression of MSH2, MSH3 or MSH6 in lymphoid cells (TK6) and myeloid leukemic cells (HL-60) (Figure 2a) . Lentiviral particles containing short-hairpin RNA constructs targeting MSH2, MSH3 or MSH6 were used to transduce TK6 or HL-60, according to the manufacturers protocols (Sigma-Aldrich, Dorset, UK). Stably transfected cells were selected and maintained by transfer to cell culture medium supplemented with 2 mg/ml puromycin. Knockdown of MSH2 resulted in complete loss of hMSH2 protein in both HL-60 (HL-60 MSH2i) and TK6 (TK6 MSH2i), accompanied by complete loss of both hMSH3 and hMSH6. MSH3 knockdown resulted in nearcomplete loss (approximately 95%) of hMSH3 in both HL-60 (HL-60 MSH3i) and TK6 (TK6 MSH3i), but there was no observed effect on hMSH2 or hMSH6. Knockdown of MSH6 completely abolished hMSH6 protein (HL-60 MSH6i and TK6 MSH6i), and was accompanied by an approximate 50% decrease in hMSH2 but did not affect hMSH3 expression relative to respective parental cell lines.
Cells depleted for either hMSH2 or hMSH6 demonstrated tolerance to the cytotoxic effects of MNU (Figure 2b ) and 6-TG ( Figure 2c ) compared with respective parental cell lines, consistent with the phenotype expected in MutSa-defective cells when exposed to these agents. Depletion of hMSH3 had no effect on cytotoxicity induced by MNU or 6-TG (Figures 2b  and c) , confirming that the MutSb complex has no role in mediating cytotoxicity in response to these agents.
Like MSH6-mutated MT-1, cells depleted in hMSH2 or hMSH6 were sensitive to the cytotoxic effects of Ara-C, clofarabine and fludarabine relative to their respective parental cells (Figures 3a-c) . In contrast, both TK6 and HL-60 cells deficient in hMSH3 were consistently resistant to the cytotoxic effects of Ara-C, clofarabine and fludarabine (Figures 3a-c) . We treated all isogenic cell lines with UV radiation and observed no differences in sensitivity in any of the cell lines relative to parental cells (Figure 3d) .
Taken together, these data demonstrate that DNA MMR status affects cellular response to Ara-C and other nucleoside analogs, and also suggests that the mode of interaction between DNA MMR components and nucleoside analogs is defect-specific, and different to that postulated for 6-TG. 
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A number of possible explanations could account for these findings, and it should be noted that they are not necessarily mutually exclusive. First, we can speculate that unlike 6-TG, Ara-C and other nucleoside analogs induce substrates in DNA recognized by MutSb, as well as MutSa. Indeed, the observation that hMSH3 loss confers resistance to the cytotoxic effects of nucleoside analogs suggests a role for MutSb. Second, it is also possible that some lesions induced by Ara-C, clofarabine and fludarabine can be successfully repaired by DNA MMR. Sensitization to nucleoside analog-induced killing in MutSadeficient cells is consistent with this model. A third possible explanation is that some DNA MMR components are also involved in other repair pathways, which may be invoked following exposure to nucleoside analogs. Homologous recombination repair is the primary repair mechanism for doublestrand breaks occurring at stalled replication forks. 5 Potential deregulation of homologous recombination repair, as a consequence of DNA MMR loss, therefore represents a mechanism that could confer sensitivity to nucleoside analog-induced cytotoxicity, as we have observed.
There is mounting evidence that DNA MMR components can modulate cellular response to other chemotherapeutic nucleoside analogs, including 5-fluorouracil, although the mode of interaction remains to be determined. 5-fluorouracil-mispaired opposite guanine is recognized by MutSa, and studies have reported resistance to 5-fluorouracil-induced cytotoxicity in cell lines deficient in components of DNA MMR. 6 Similarly, there is some evidence that DNA MMR components might also have a role in modulating in vitro response to gemcitabine, a nucleoside analog of deoxycytidine also used to treat leukemia. Notably, Takahashi et al. 7 reported gemcitabine to be more toxic to hMLH1-deficient cells than their MMR-proficient counterparts. Although these data suggest involvement of DNA MMR components in response to nucleoside analogs, they do not confirm a role for the DNA MMR pathway per se, as response could be mediated through other pathways in which MMR components participate, as we have suggested.
Exposure to methylating agents and 6-TG contribute to t-AML etiology through a mechanism involving the loss of DNA MMR and the acquisition of genomic instability. A growing body of evidence has highlighted a possible association between t-AML and previous nucleoside analog therapy. For example, a multicentre study reported that chronic lymphocytic leukemia patients treated with fludarabine were at increased risk of developing t-AML. 8 Although our data demonstrate a role for DNA MMR components in mediating cellular response to fludarabine and other nucleoside analogs, it remains to be determined whether these agents facilitate the development of t-AML through loss of DNA MMR.
Defective DNA MMR, as evidenced by high levels of microsatellite instability, is often associated with AML subgroups classified as high risk, such as elderly patients and those with relapsed or therapy-related disease. 2, 3 Furthermore, specific DNA MMR defects, including MSH2 mutation and loss of protein expression, have been reported in high-risk patients. Given the increasing use of clofarabine in the treatment of elderly and other high-risk AML subgroups, our data suggest that DNA MMR status may be a relevant prognostic factor. In summary, we have shown that DNA MMR status affects cellular response to the cytotoxic effects of nucleoside analogs, and these data suggest that the development of tailored chemotherapeutic regimens to exploit differences in DNA repair status could be of clinical use.
